The Biggest Challenges Facing Expanded Access Programs—and How Leading Pharmaceutical Companies Are Responding

Expanded Access (EA), also known as Compassionate Use outside the United States, has become an increasingly important component of modern drug development. Once viewed primarily as a mechanism to help individual patients with no remaining treatment options, Expanded Access programs are now strategic initiatives that enable biopharmaceutical companies to support patients, strengthen relationships with healthcare providers, and generate valuable operational and clinical insights.

As innovative therapies continue to emerge—particularly in oncology, rare diseases, and cell and gene therapy—the demand for Expanded Access has grown significantly. At the same time, regulatory requirements have become more complex, global programs have expanded, and expectations from physicians and patients have never been higher.

For pharmaceutical companies, the challenge is no longer simply approving requests. It is building scalable, compliant, and efficient programs capable of supporting patients around the world.

1. Growing Demand Is Stretching Internal Resources

Medical Affairs teams are managing an increasing number of requests from physicians seeking treatment options for patients with serious or life-threatening conditions. While every request represents an opportunity to help a patient, each also requires careful review, coordination, and documentation.

Many organizations continue to rely on email, spreadsheets, and manual tracking processes, creating administrative burdens that slow response times and increase the risk of errors. As request volumes rise, these approaches become increasingly difficult to sustain.

The challenge is no longer handling a handful of requests each month—it is building processes that can scale without requiring proportional increases in headcount.

2. Navigating a Complex Global Regulatory Environment

Expanded Access is governed differently across countries. Every market may have unique regulatory requirements, documentation standards, ethics committee processes, import regulations, and reporting obligations.

For global pharmaceutical companies, this often means managing dozens of country-specific workflows simultaneously. Maintaining consistency while accommodating local regulations requires standardized governance combined with enough flexibility to adapt to regional requirements.

Organizations that lack centralized processes often find themselves recreating documentation, duplicating work, and struggling to maintain visibility across international programs.

3. Coordinating Multiple Departments Around a Single Patient

An Expanded Access request rarely involves just one department.

Medical Affairs evaluates clinical appropriateness. Regulatory Affairs oversees submissions. Supply Chain confirms product availability. Pharmacovigilance manages safety reporting. Legal reviews agreements. Manufacturing, Quality, and Clinical Operations frequently play important supporting roles.

Without centralized coordination, information becomes fragmented across emails, shared drives, and disconnected systems. Delays, duplicate work, and communication gaps become increasingly common.

Successful programs depend on bringing every stakeholder together through standardized workflows and clear visibility into each request.

4. Balancing Drug Supply with Patient Need

One of the most difficult decisions companies face is determining how to allocate limited drug supply.

Sponsors must balance the needs of clinical trials, manufacturing capacity, future commercial launch requirements, and individual patient requests. These decisions become particularly challenging for personalized medicines, cell and gene therapies, and products with limited manufacturing capacity.

Establishing transparent governance frameworks helps organizations make consistent, ethical, and defensible decisions while ensuring equitable patient access.

5. Ensuring Compliance Without Creating Administrative Burden

Expanded Access programs operate within a highly regulated environment. Every request requires careful documentation, approvals, safety reporting, and complete audit trails.

Regulatory inspections increasingly focus not only on clinical outcomes but also on how organizations document decisions, manage approvals, and maintain data integrity throughout the program lifecycle.

Companies are seeking ways to strengthen compliance while reducing manual administrative work through standardized workflows, electronic documentation, and centralized records.

6. Capturing Valuable Real-World Data

Expanded Access programs have historically focused on providing treatment rather than collecting data. Today, many sponsors recognize that these programs can also contribute meaningful real-world insights.

When appropriate and compliant with applicable regulations, organizations are exploring ways to collect structured information on treatment outcomes, safety observations, quality of life, and long-term follow-up.

Capturing this information efficiently requires processes that minimize the burden on physicians while ensuring data quality and consistency.

7. Delivering a Better Experience for Physicians and Patients

Physicians often navigate multiple forms, repeated requests for information, and lengthy email chains simply to submit a patient request.

Patients and families, meanwhile, are often waiting during some of the most difficult moments of their lives.

Improving the physician experience through simplified submission processes, transparent communication, and faster response times ultimately improves the patient experience as well. Organizations increasingly recognize that operational excellence is not just an efficiency goal—it directly supports patient care.

8. Gaining Visibility Through Better Data

Leadership teams increasingly want answers to important operational questions:

• How many requests are being received globally?

• Which countries generate the highest demand?

• How long does approval take?

• Where are bottlenecks occurring?

• What resources are required to support future growth?

Without centralized reporting, answering these questions often requires manual data collection from multiple systems.

Real-time dashboards and standardized reporting help organizations identify trends, improve forecasting, and make more informed strategic decisions.

Looking Ahead: Building Programs That Can Scale

Expanded Access programs are becoming an increasingly important extension of Medical Affairs strategy and patient access initiatives. As therapies become more specialized and global demand continues to grow, organizations need operational models that can evolve alongside their programs.

Leading pharmaceutical companies are focusing on several key priorities:

• Standardizing governance across global operations.

• Reducing manual administrative work through workflow automation.

• Improving collaboration across Medical Affairs, Regulatory, Supply Chain, Quality, and Pharmacovigilance.

• Strengthening compliance with centralized, inspection-ready documentation.

• Capturing operational insights and real-world data that support continuous improvement.

• Delivering a faster, more transparent experience for physicians and patients.

Technology alone is not the solution, but purpose-built platforms are becoming an important enabler of these objectives. By replacing fragmented processes with centralized workflows, organizations can reduce complexity, improve visibility, and better support both internal teams and the patients they ultimately serve.

Conclusion

Expanded Access programs are no longer peripheral initiatives managed through spreadsheets and email. They have become strategic, global operations that require strong governance, cross-functional collaboration, and scalable technology.

As demand continues to rise, pharmaceutical companies that invest in modernizing their Expanded Access operations will be better positioned to deliver timely patient access, maintain regulatory compliance, and generate insights that strengthen future programs.

At MedaSystems, we believe technology should simplify complexity—not add to it. By helping organizations streamline workflows, centralize collaboration, and improve operational visibility, we enable pharmaceutical companies to focus on what matters most: providing patients with access to potentially life-changing therapies when they need them most.